| | | 粘附分子整合素α5 β1在胆囊癌中的表达及其临床意义
| | 临床医学检验论文【摘要】 目的临床医学检验论文 研究粘附分子整合素α5β1在胆囊腺癌中的临床医学检验论文表达及其与胆囊腺癌分化、侵袭转移和预后的关系。方法 应用免疫组织化学方法对57例胆囊腺癌石蜡包埋标本进行整合素α5β1半定量检测。结果 有41例(71.9%)胆囊腺癌组织整合素α5β1表达减弱或消失,高分化癌的整合素α5 β1阳性率明显高于低分化癌(P<0.05)。整合素α5β1阳性率在胆囊癌伴淋巴结转移组低于淋巴结阴性组(P<0.05)。整合素α5β1表达阳性者2年生存率(32.5%)显著高于表达阴性者(11.3%,P<0.05)。结论 整合素α5β1表达与肿瘤细胞的分化程度、淋巴结转移呈负相关,整合素α5β1表达与患者预后相关,可作为判断胆囊癌患者预后的生物学指标。 Expression of integrin α5 β1 in adenocarcinoma of gallbladder and its clinical implication 【Abstract】 ObjectiveTo investigate the integrin α5 β1 expression in adenocarcinoma of gallbladder and its relation with tumor differentiation, invasion, metastasis and prognosis.Methods The integrin α5 β1 expression was detected in 57 cases of gallbladder adenocarcinoma by using immunohistochemistry technique (PAP method) and 37 cases of chronic cholecystitis.Results The expression of integrin α5 β1 in71.9 % cases of gallbladder carcinoma and 13.5 % cases of chronic cholecystitis was weaker than in the surrounding normal cholecystic mocusa. The positive rate of integrin α5 β1 was lower in poorly differentiated carcinoma group than in well differentiated group (P<0.05). The positive& nbsp;rate of integrin α5 β1 was lower in metastatic carcinoma group than in non-metastatic group (P<0.05). the two-year survival rate was higher in integrin α5 β1 positive group (32.5%) than in negative group (11.3 %, P<0.05).Conclusion The weak or loss expression of integrin α5 β1 was related with differentiation and metastasis of gallbladder carcinoma. The expression of integrin α5 β1 might have prognostic value. 【Key words】 Gallbladder adenocarcinoma; Integrinα5 β1; Immunohistochemistry 胆囊癌发病率逐年升高,占胆道系统恶性肿瘤的64.7%。我们应用免疫组织化学方法检测57例胆囊腺癌石蜡包埋标本中粘附分子整合素(integrin)α5β1的表达并探讨其意义。 对象和方法 1.病例选择:1988~1994年上海医科大学附属华山医院和中山医院手术切除的原发性胆囊癌病例标本57例,其中男22例,女35例,年龄36~81岁,平均56岁。按1991年WHO病理分类标准,57例均为胆囊腺癌,其中高分化癌18例,分化中等癌26例,分化差的癌13例。依据1987年UICC的胆囊癌TNM分期标准:T1期19例,T2期15例,T3期17例,T4期6例。57例中有37例(64.9%)合并有胆囊结石。取同期37例慢性胆囊炎的标本作为对照。 2.标本制备及免疫组化染色:兔抗人整合素α5 β1多抗为Sigma公司产品,羊抗兔IgG与兔PAP试剂为Vecter实验室产品。标本经福马林固定、石蜡包埋、连续切取2张5μm厚切片,1张作常规HE染色外,另1张用于检测整合素α5 β1表达。免疫组化染色采用PAP法。 3.整合素α5 β1染色结果判定标准:按肿瘤细胞着色强度及阳性细胞分布范围分为4个等级:无细胞着色(-);10%~30%细胞呈弱、中等强度阳性反应(+);30%细胞呈强阳性反应或30%~60%细胞呈弱、中等强度阳性反应();>60%细胞呈强阳性反应()。
| | | |
| | | | <<<<<全文未完>>>>> 全文字数约2001字 | |
| | |
| |
|